Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ALK |
| Variant | del exon2-19 |
| Impact List | deletion |
| Protein Effect | unknown |
| Gene Variant Descriptions | ALK del exon2-19 indicates the deletion of exons 2-19 of the ALK gene. |
| Associated Drug Resistance | |
| Category Variants Paths |
ALK mutant ALK del exon2-19 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK del exon2-19 | lung adenocarcinoma | predicted - sensitive | Alectinib | Case Reports/Case Series | Actionable | In a clinical case study, Alecensa (alectinib) treatment resulted in a complete response lasting at least 23 months in a patient with metastatic lung adenocarcinoma harboring a deletion of ALK exons 2-19 (PMID: 36994308). | 36994308 |